drugset
drugset / Trial / NCT01897831

Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

NCT01897831 ↗

Phase 4 Unknown 2000 enrolled Xiangbei Welman Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.

Timeline

Start
2011-08
Primary completion
2015-08
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Piperacillin Small molecule 1 g Intravenous
Subject Piperacillin Small molecule 2 g Intravenous
Subject Piperacillin Small molecule 4 g Intravenous
Subject Piperacillin Small molecule 8 g Intravenous
Subject Sulbactam Small molecule 0.5 g Intravenous
Subject Sulbactam Small molecule 1 g Intravenous
Subject Sulbactam Small molecule 2 g Intravenous
Subject Sulbactam Small molecule 4 g Intravenous

Indications

respiratory tract infectious disorder urinary tract infection